These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35600160)

  • 1. Novel approach to antiangiogenic factors in age-related macular degeneration therapy.
    Samelska K; Kupis M; Izdebska J; Kaminska A; Skopiński P
    Cent Eur J Immunol; 2022; 47(1):117-123. PubMed ID: 35600160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement inhibitors for age-related macular degeneration.
    Tzoumas N; Riding G; Williams MA; Steel DH
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD.
    Śpiewak D; Drzyzga Ł; Dorecka M; Wyględowska-Promieńska D
    J Clin Med; 2024 Jul; 13(14):. PubMed ID: 39064267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
    Cabral de Guimaraes TA; Daich Varela M; Georgiou M; Michaelides M
    Br J Ophthalmol; 2022 Mar; 106(3):297-304. PubMed ID: 33741584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Linkage between Angiogenesis and Inflammation in Neovascular Age-Related Macular Degeneration.
    Heloterä H; Kaarniranta K
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
    Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
    Geltzer A; Turalba A; Vedula SS
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005022. PubMed ID: 17943833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
    Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
    Yang S; Zhao J; Sun X
    Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X; Sun X
    Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of antiangiogenic agents in age related macular degeneration].
    Tomi A
    Oftalmologia; 2010; 54(4):63-72. PubMed ID: 21516865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pipeline therapies for neovascular age related macular degeneration.
    Arepalli S; Kaiser PK
    Int J Retina Vitreous; 2021 Oct; 7(1):55. PubMed ID: 34598731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Advances in the Treatment of Age-related Macular Degeneration.
    Gil-Martínez M; Santos-Ramos P; Fernández-Rodríguez M; Abraldes MJ; Rodríguez-Cid MJ; Santiago-Varela M; Fernández-Ferreiro A; Gómez-Ulla F
    Curr Med Chem; 2020; 27(4):583-598. PubMed ID: 31362645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neovascular age-related macular degeneration: potential therapies.
    Chappelow AV; Kaiser PK
    Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
    Geltzer A; Turalba A; Vedula SS
    Cochrane Database Syst Rev; 2013 Jan; 1(1):CD005022. PubMed ID: 23440797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical macular hole formation after Anti-VEGF therapy for neovascular age-related macular degeneration: Coincidence or consequence?
    Kayaarasi Ozturker Z; Akca Bayar S; Yaman Pinarci E; Kurt RA; Akkoyun I; Yilmaz G
    Arch Soc Esp Oftalmol (Engl Ed); 2021 Sep; 96(9):455-461. PubMed ID: 34479701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.